Freudenthal B, Williams G R
Molecular Endocrinology Laboratory, Imperial College London, London, UK.
Molecular Endocrinology Laboratory, Imperial College London, London, UK.
Clin Oncol (R Coll Radiol). 2017 May;29(5):325-328. doi: 10.1016/j.clon.2016.12.011. Epub 2016 Dec 30.
Differentiated thyroid cancer is the most common form of thyroid cancer and its prognosis is favourable in most cases. Suppression of thyroid stimulating hormone (TSH) by supra-physiological thyroid hormone replacement has been the mainstay of long-term management for over 60 years. However, evidence for a beneficial outcome of TSH suppression is conflicting and intervention must be balanced against adverse effects, particularly affecting the cardiovascular system and skeleton. Here we discuss the role of TSH suppression in the long-term management of differentiated thyroid cancer in the context of risk stratification for disease recurrence and the latest clinical guidelines.
分化型甲状腺癌是甲状腺癌最常见的形式，在大多数情况下其预后良好。超生理剂量甲状腺激素替代抑制促甲状腺激素（TSH）60多年来一直是长期治疗的主要手段。然而，TSH抑制产生有益结果的证据存在矛盾，干预措施必须在不良反应（特别是对心血管系统和骨骼的影响）之间取得平衡。在此，我们结合疾病复发风险分层和最新临床指南，讨论TSH抑制在分化型甲状腺癌长期治疗中的作用。
